Cargando…

Association of Renal Function and Direct-Acting Antiviral Agents for HCV: A Network Meta-Analysis

The effectiveness and safety of direct-acting antiviral agents (DAAs) in hepatitis C virus (HCV) patients with renal insufficiency remain controversial. Therefore, this network meta-analysis aims to assess effectiveness and safety of DAAs in populations with different renal function. The pooled data...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kao, Chih-Chin, Lin, Yu-Shiuan, Chu, Heng-Cheng, Fang, Te-Chao, Wu, Mai-Szu, Kang, Yi-No
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210726/ https://www.ncbi.nlm.nih.gov/pubmed/30274298 http://dx.doi.org/10.3390/jcm7100314

Ejemplares similares

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents
por: Angeletti, Andrea, et al.
Publicado: (2019)

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
por: La Manna, Gaetano
Publicado: (2018)

Direct-Acting Antiviral Agents for HCV-Associated Glomerular Disease and the Current Evidence
por: Fabrizi, Fabrizio, et al.
Publicado: (2019)

Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients
por: Armando, Calogero, et al.
Publicado: (2019)

HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals
por: Rice, Donald P., et al.
Publicado: (2016)

Erratum to “Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients”
por: Calogero, Armando, et al.
Publicado: (2019)

Recent Information on Pan-Genotypic Direct-Acting Antiviral Agents for HCV in Chronic Kidney Disease
por: Fabrizi, Fabrizio, et al.
Publicado: (2022)

Liver Fibrosis Regression and Associated Factors in HCV Patients Treated with Direct-Acting Antiviral Agents
por: Abu-Freha, Naim, et al.
Publicado: (2023)

B-cell Clonality in HCV-Induced Patients Treated with Oral Direct-Acting Antiviral Agents
por: Waly, Basma, et al.
Publicado: (2023)

The ‘Viennese epidemic’ of acute HCV in the era of direct‐acting antivirals
por: Chromy, David, et al.
Publicado: (2022)

Cardiac Toxicity Associated with HCV Direct Antiviral Agents
por: Ucciferri, Claudio, et al.
Publicado: (2018)

Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis
por: Kawagishi, Naoki, et al.
Publicado: (2018)

Transplantation of HCV Viremic Livers into HCV Viremic Recipients Followed by Direct-acting Antiviral Therapy
por: Kapila, Nikhil, et al.
Publicado: (2019)

Remission of long-term hepatic and renal disease induced by HCV after direct-acting antivirals therapy
por: Arruda, Raissa M, et al.
Publicado: (2020)

Assessment of Renal Function in Post-Liver Transplant HCV-Positive Patients Treated with Direct Acting Antivirals
por: Elzorkany, Khaled, et al.
Publicado: (2020)

Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
por: Stevenson, Heather L., et al.
Publicado: (2016)

Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation
por: Martin, Natasha K., et al.
Publicado: (2016)

Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data
por: Chen, Zhi-wei, et al.
Publicado: (2016)

Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)
por: Dold, L., et al.
Publicado: (2019)

HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients
por: Brochado-Kith, Óscar, et al.
Publicado: (2021)

Direct Binding of Ledipasvir to HCV NS5A: Mechanism of Resistance to an HCV Antiviral Agent
por: Kwon, Hyock Joo, et al.
Publicado: (2015)

Resistant-Associated Substitutions Do Not Affect HCV RNA and HCV Core Antigen Clearance During Direct-Acting Antiviral Agent Treatment in a Real-World Setting
por: Chen, Hongyu, et al.
Publicado: (2022)

Genetic Barrier to Direct Acting Antivirals in HCV Sequences Deposited in the European Databank
por: Kliemann, Dimas Alexandre, et al.
Publicado: (2016)

Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV
por: Patel, Sonia Vibhakar, et al.
Publicado: (2020)

Screening and surveillance of oesophageal varices in patients with HCV‐positive liver cirrhosis successfully treated by direct‐acting antiviral agents
por: Ciancio, Alessia, et al.
Publicado: (2022)

Telomere Length Increase in HIV/HCV-Coinfected Patients with Cirrhosis after HCV Eradication with Direct-Acting Antivirals (†)
por: Molina-Carrión, Silvia, et al.
Publicado: (2020)

Baseline Plasma Metabotype Correlates With Direct-Acting Antiviral Therapy Nonresponse for HCV in HIV–HCV Coinfected Patients
por: Tripathi, Gaurav, et al.
Publicado: (2022)

Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral Agents
por: Sanduzzi-Zamparelli, Marco, et al.
Publicado: (2019)

Direct antiviral agents for HCV infection and hepatocellular carcinoma: facts and FADs
por: Serio, Ilaria, et al.
Publicado: (2019)

Augmenting central arterial stiffness following eradication of HCV by direct acting antivirals in advanced fibrosis patients
por: Cheng, Pin-Nan, et al.
Publicado: (2019)

Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination
por: Virlogeux, Victor, et al.
Publicado: (2017)

2223. Effect of Direct-Acting Antivirals in Hemodialysis Patients with HCV: Real-Life Data
por: Aydin, Nurten Nur, et al.
Publicado: (2018)

Direct‐acting antivirals ability to clear intestinal HCV‐RNA in liver transplant patients
por: Pietrosi, Giada, et al.
Publicado: (2020)

Resolved HBV behavior during the treatment of chronic HCV infection with direct-acting antivirals
por: Mohamed, Salem Y., et al.
Publicado: (2019)

Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs
por: Minosse, Claudia, et al.
Publicado: (2021)

Long term changes in thrombocytopenia and leucopenia after HCV eradication with direct-acting antivirals
por: Tajiri, Kazuto, et al.
Publicado: (2023)

356. HIV-HCV Coinfection: An Investigation of CD4 T-Cell Reconstitution after HCV Direct-Acting Antiviral Treatment
por: Michienzi, Sarah M, et al.
Publicado: (2019)

T-cell Activation Is Correlated With Monocyte Activation in HCV/HIV Coinfection and Declines During HCV Direct-Acting Antiviral Therapy
por: Auma, Ann W N, et al.
Publicado: (2021)

HIV tropism switch in archived DNA of HIV-HCV subjects successfully treated with direct-acting antivirals for HCV infection
por: Basso, Monica, et al.
Publicado: (2021)

Factors Associated with Large Renal Function Decline in Patients with Chronic Hepatitis C Successfully Treated with Direct-Acting Antiviral Therapy
por: Chen, Chun-Hsien, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cqbueph4gock4jelf7v4l58t7c